| CTRI Number |
CTRI/2025/02/079988 [Registered on: 06/02/2025] Trial Registered Prospectively |
| Last Modified On: |
27/04/2026 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Medical Device |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
Cancer Diagnostic probe (CDP) medical device which is used for product validation and safety, sensitivity, and Accuracy concern Cancer Diagnostic Probe (CDP) for the detection of cancer cell during Breast Cancer Surgery - A Multicenter collaborative Observational Project. |
|
Scientific Title of Study
|
Assessment of safety, sensitivity, and Accuracy of Cancer Diagnostic Probe (CDP) for the detection of cancer cell during Breast Cancer Surgery - A Multicenter collaborative Pilot Project. |
| Trial Acronym |
CT-CDP |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Ashutosh Mishra |
| Designation |
Associate Professor, Room No. 244, Department of Surgical Oncology |
| Affiliation |
All India Institute of Medical Sciences, New Delhi, India |
| Address |
All India Institute of Medical Sciences, New Delhi, Ansari Nagar East, New Delhi
South DELHI 110029 India |
| Phone |
9650638722 |
| Fax |
|
| Email |
drashutoshmishra11@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Ashutosh Mishra |
| Designation |
Associate Professor, Room No. 244, Department of Surgical Oncology |
| Affiliation |
DR BRA-IRCH All India Institute of Medical Sciences, New Delhi, India |
| Address |
DR BRA-IRCH
All India Institute of Medical Sciences, New Delhi, India
South DELHI 110029 India |
| Phone |
9650638722 |
| Fax |
|
| Email |
drashutoshmishra11@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Ashutosh Mishra |
| Designation |
Associate Professor, Room No. 244, Department of Surgical Oncology |
| Affiliation |
DR BRA-IRCH All India Institute of Medical Sciences, New Delhi, India |
| Address |
DR BRA-IRCH
All India Institute of Medical Sciences, New Delhi, India
South DELHI 110029 India |
| Phone |
9650638722 |
| Fax |
|
| Email |
drashutoshmishra11@gmail.com |
|
|
Source of Monetary or Material Support
|
| Coosa Technologies Private Limited |
|
|
Primary Sponsor
|
| Name |
Coosa Technologies Private Limited |
| Address |
FF, Farm No. 7, Club drive Road, Ghitorni, New Delhi - 110030 |
| Type of Sponsor |
Other [Medical Device Company] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
Sites of Study
Modification(s)
|
| No of Sites = 5 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Ashutosh Mishra Associate Professor |
All India Institute of Medical Sciences |
Department of Surgical Oncologist Room no. 244, East Ansari Nagar, New Delhi New Delhi DELHI |
9650638722
drashutoshmishra11@gmail.com |
| Dr Ramesh Sarin Senior Consultant |
Indraprastha Apollo Hospitals |
Sarita Vihar Delhi-Mathura Road
New Delhi - 110076 India
New Delhi DELHI |
9810322237
drmrsrameshsarin@gmail.com |
| Dr SVS Deo |
Max Super speciality Hospital |
No. 1, 2, Press Enclave Road, Mandir Marg, Saket Institutional Area, Saket, New Delhi, 110017, India New Delhi DELHI |
9811356594
SVS.Deo@maxhealthcare.com |
| Dr Kanchan Kaur Senior Director |
Medanta - The Medicity |
Sector-38, Gurgaon, Haryana Gurgaon HARYANA |
9910388933
kanchan.kaur@medanta.org |
| Dr Vivek Gupta Senior Consultant |
Pushpawati Singhania Hospital & Research Institute |
Phase 2, Sheikh Sarai, Delhi 110017 India South DELHI |
9990057517
dr.vivekgupta@hotmail.com |
|
Details of Ethics Committee
Modification(s)
|
| No of Ethics Committees= 5 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee, Devki Devi Foundation |
Approved |
| All India Institute of Medical Sciences (AIIMS) |
Approved |
| Indraprastha Apollo Hospitals |
Approved |
| Medanta - The Medicity |
Approved |
| Pushpawati Singhania Hospital & Research Institute |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Cancer Diagnostic Probe |
1. Generic Name :Cancer Diagnostic Probe
2. Brand Name(if registered under the Trade Marks Act, 1999) :Coosa
3. Notified Category :Cancer diagnostic Probe
4. Class of Medical Device :Class C
5. Shelf life :10 years
6. Sterilization:Non-Sterilized
7. Contains Drugs:No
8. Medical Device Grouping Category : Single
9. Grouping Description: NIL
10. Intended Use :Cancer Diagnostic probe can be intended for diagnosis of breast Cancer
in all age groups and genders.
11. Product Description: CDP can be used for patients of all ages and genders with breast
tumor disease who are candidates for breast-conserving surgery either in adjuvant/nonneoadjuvant
cases. The cavity side margins of different histologic subtypes of breast tumors
such as invasive ductal carcinoma, invasive lobular carcinoma, malignant phyllodes tumor,
atypical ductal hyperplasia, and ductal carcinoma in situ could be checked by CDP
intraoperatively. It can also assess the cavity side margins of breast cancer patients who have
undergone surgery for first-line treatment, post-neoadjuvant, recurrency, and involved
margins. Additionally, CDP can be used to check the intraoperative dissected lymph node
status in breast cancer surgery. The CDP device is composed of three main parts: "a
disposable sensor; a wireless electrical head probe used by the surgeon; [and] a main control
computer system which receives the signals from the head probe. It electrochemically
measures the hypoxia glycolysis metabolism in real-time "in pre-cancerous and cancerous
lesions in cavity side margins". It measures the release of H2O2 from cancer or atypical cells
by the reverse Warburg effect.
12. Material of Construction: Li-Ion battery, Electrodes, Display panel and bluetooth
software
13. Dimension:
14. Storage Condition: Room Temperature
14. Pack Size: Single Unit
15. Accessory: NIL
16. Model No. :SG 1 - Portable Cancer Diagnostic Probe 7.4 V
17. Equivalence to predicte device :No |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
65.00 Year(s) |
| Gender |
Both |
| Details |
The following inclusion criteria will be considered for the study CDP can be used for patients of all ages and genders with breast tumor disease who are candidates for breast conserving surgery in adjuvant non neoadjuvant cases.
|
|
| ExclusionCriteria |
| Details |
Patients with the following will be excluded from the study
1. Patients with non palpable tumor
2. Patients exhibiting post NACT complete response
All patients diagnosed with breast cancer which were candidates for breast conserving surgery. All the patients will be informed about the process and sign the consent before the surgery. The patient gender, age, and surgical history, and adjuvant or neoadjuvant chemotherapy are not effective parameters for the patient recruitment. |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| We will provide the primary outcomes data In process Clinical trial observations. |
Secondary outcome data will start on after 6 Weeks. |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To observe the results after the pathology findings. |
based on observational study data which comes after 14 weeks. |
|
|
Target Sample Size
|
Total Sample Size="50" Sample Size from India="50"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
15/03/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="0" Months="3" Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Open to Recruitment |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - YES
- What data in particular will be shared?
Response - All of the individual participant data collected during the trial, after de-identification.
- What additional supporting information will be shared?
Response - Study Protocol Response - Statistical Analysis Plan Response - Informed Consent Form Response - Clinical Study Report Response - Analytic Code
- Who will be able to view these files?
Response - Researchers who provide a methodologically sound proposal.
- For what types of analyses will this data be available?
Response - For individual participant data meta-analysis.
- By what mechanism will data be made available?
Response - Proposals should be directed to [ravimittal@coosa.in].
- For how long will this data be available start date provided 01-07-2025 and end date provided 30-06-2028?
Response - Beginning 9 months and ending 36 months following article publication.
- Any URL or additional information regarding plan/policy for sharing IPD?
Additional Information - NIL
|
Brief Summary
Modification(s)
|
Full Title of the Study: Assessment of safety, sensitivity, and Accuracy of Cancer Diagnostic Probe (CDP) for the detection of cancer cell during Breast Cancer Surgery - A Multicenter collaborative Pilot Project.
Objectives of the study : · Primary Objectives: 1. To assess the safety, sensitivity, and accuracy of Cancer Diagnostic Probe (CDP) for breast cancer detection during Breast cancer surgery. · Secondary Objectives: 1. To detect cancer cell at the margin of post lumpectomy cavity wall 2. To compare the sensitivity of CDP and Frozen section in breast cancer surgery 3. To compare the sensitivity of CDP and Frozen section in detecting Cancer cells in Sentinel Lymph Node. Justification for conduct of this study Breast cancer (BC) is the most prevalent malignant solid tumor among women worldwide, and Breast Conserving Surgery (BCS) has been proven as the best surgery method for early-stage BC patients in clinical studies. Remained positive margins is still a moot point with drastic impact on risk of cancer recurrence. Residue of tumor cells in cavity side may induce dangerous challenge as they are in interaction with accumulated cytokines (in surgical bed fluid). Therefore, it is imperative to develop effective strategies to minimize involved margins and ensure optimal results for patients. Up to 20 % of the margins may remain positive despite utilizing conventional intra-operative methods. In addition, the frozen section is a time-consuming, expensive and labor-intensive process, adding the risk of false negatives (6-20%) owing to technical limitations such as incomplete fixation of pathology samples. Bioelectronic science has emerged as a novel strategy in cancer research, allowing discrimination between cancerous and non-cancerous cells and tissues, broadening the horizon of cancer research. A recently developed technique, the Cancer diagnostic probe (CDP) (granted USA patents: US 11,179,076 B2, US 10,786,188 B1, US 11,179,077 B2, US 11,181,499 B2, US 11,806,140 B2), has been known as another complementary electrical method, which shed new lights in real-time diagnosing the presence of pre-cancerous and cancerous cells in cavity margins of breast tumors via the assistance of electrical probing on biochemical metabolism of the live cells in the margins.This highlights the impact of CDP as an innovative intraoperative technique to evaluate cavity side margins effectively. Methodology:
| Study site and Design: · This is a prospective pilot study, and the study will be carried out in the Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India. · A total of 50 patients confirming the diagnosis of breast cancer. Patient Recruitment and Sample Collection: · Ethical approval for the study will be taken from the Institute Ethics Committee, All India Institute of Medical Sciences (AIIMS), New Delhi, India. · Each patient will be enrolled after approval from EIC with their written informed consent. · For the study, prospectively selected n=50 patients with tumor will be recruited, irrespective of their treatment status. CDP will be applied on tumor and normal cells during surgery (MRM/ Breast Conserving Surgery). Hence the tumor cell, normal cells, cavity margins and sentinel LN will be assessed by CDP. The results will be observed accordingly and further correlated with histopathology report. | Inclusion and Exclusion Criteria: | The following inclusion criteria will be considered for the study
CDP can be used for patients of all ages and genders with breast tumor disease who are candidates for breast-conserving surgery in adjuvant/non-neoadjuvant cases.
| Patients with the following will be excluded from the study: 1. Patients with non-palpable tumor 2. Patients exhibiting post-NACT complete response All patients diagnosed with breast cancer, which were candidates for breast-conserving surgery. All the patients will be informed about the process and sign the consent before the surgery. The patient’s gender, age, and surgical history, and adjuvant or neoadjuvant chemotherapy are not effective parameters for the patient’s recruitment. The workflow of the proposed study is as follows | This is a multicenter pilot study for evaluating the safety, sensitivity, and Accuracy of a Cancer Diagnostic Probe (CDP) for the detection of cancer cells in-vivo during Breast Cancer Surgery and subsequently, results obtained by the CDP probe will be compared with gold standard histopathology of the same cavity lesion recorded by CDP. During breast-conserving surgery, the surgeon will apply the CDP on cavity side margins (CDP electrodes should be inserted up to 4 mm) after resection of the tumor (the resected tumor will be sent for a frozen section and then permanent pathology (pathological evaluation on tumor side margins)). Surgeons will not be biased toward the CDP scoring results. So, all negatively and positively scored lesions will be re-excised for pathological evaluation. The size of each excised lesion will be about 1×1×1 cm3. These samples are called as “CDP Samplesâ€. The required time for checking all of the margins by CDP is about 10 min. | CDP Samples will be sent for permanent pathology to be evaluated pathologically as the gold standard. At this stage, the pathologist must be blinded to the CDP results. In this manner, we have no bias during the trial and the score of CDP does not affect the decision of the surgeon and pathologist while all of the data will be compared with an accepted gold standard. Independently the tumor (the resected tumor) will be sent for a frozen section and then permanent pathology (pathological evaluation on tumor side margins). Finally, after the collection of all lesions in fixed block samples (cavity side lesions recorded by CDP), the lesions will be sent for H&E slide sectioning, and independent and blind pathologists will evaluate and declare their diagnosis on the cavity lesions. Finally, the epidemiologist of the project will integrate all the data and report two tables. The first matching table of CDP scores by H&E of cavity margins (as sensitivity and accuracy), the second comparative table between CDP score, the frozen score of the tumor side and the permanent score of the tumor side all with the permanent score of the cavity side (gold merit) in second table the sensitivity and accuracy of frozen and permanent of tumor side will also be compared with the pathologic state of cavity side margins. Also, the cross table and ROC curve will be presented to compare the results. | | |